BYT-1007
/ BoYen Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 10, 2026
An open-label, first-in-human, dose escalation study to determine the pharmacokinetics, pharmacodynamics, tolerability and safety of BYT-1007 in patients with hematologic malignancies
(ANZCTR)
- P1 | N=20 | Not yet recruiting | Sponsor: Boyen Therapeutics Australia Pty Ltd
First-in-human • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology
1 to 1
Of
1
Go to page
1